Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi K.K.’s Payments to Healthcare Professionals Total 9.8 Billion Yen in 2012
July 31, 2013
- Ex-Novartis Employee Had Access to Pre-Locked Data: Third-Party Probe
July 31, 2013
- Novartis Paid 23.6 Billion Yen to Doctors, Medical and Research Institutions in 2012
July 31, 2013
- Novartis’s Third-Party Probe Finds “No Evidence” Indicating Data Falsification by Ex-Employee; Truth behind Diovan Woe Not Yet Uncovered
July 30, 2013
- Arbekacin Inhalation Solution Enters PI Study in US: Meiji Seika Pharma
July 30, 2013
- Medipal, Mitsubishi Acquire Shares in Chinese Pharma Wholesaler for 8 Billion Yen
July 30, 2013
- Janssen Files NDA for Prostate Cancer Treatment Abiraterone in Japan
July 30, 2013
- Kyowa Kirin’s 1st Half Sales Up 2.1%, but Mainstay Nesp Slumps 7%
July 29, 2013
- Interim Analysis of Multinational PIII Study of Orteronel Shows No Improvement of OS in Patients with mCRPC: Takeda
July 29, 2013
- Bell Medical, inVentiv to Provide Promotion and PMS Support Services
July 26, 2013
- Chugai Sales Up 8.4% Due to Increase in Cancer Treatment, Overseas Sales
July 26, 2013
- Safety of Atopic Dermatitis Treatment Confirmed in PI Study in Japan: AnGes MG
July 26, 2013
- OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines
July 26, 2013
- Can Generic Drug Industry Achieve “Zero Supply Disruptions” by FY2015? 30 Products –Largest Ever– from 14 Companies Experience Shortage in 2012
July 26, 2013
- Toho Pharmaceutical’s New Logistics Center in Hyogo Begins Operations
July 25, 2013
- Janssen Provides Free Simplified Dementia Screening Tool to Medical Institutions
July 25, 2013
- Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
- Novartis Launches Diovan OD Tablets, Sales Reps Find Promotion Difficult
July 24, 2013
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…